EGFR-Targeted Nanoparticle Delivery of Osimertinib for Triple-Negative and Metastatic Breast Cancer Therapy
Iman M. Alfagih, Maryam Alfagih, Alanood Almurshedi, Basmah Aldosari, Bushra Alquadeib, Baraa Hajjar, Shahad Almogheerah, Rund Alzahrani · 2026
Read EGFR-Targeted Nanoparticle Delivery of Osimertinib for Triple-Negative and Metastatic Breast Cancer Therapy by Iman M. Alfagih, Maryam Alfagih, Alanood Almurshedi, Basmah Aldosari, Bushra Alquadeib, Baraa Hajjar, Shahad Almogheerah, Rund Alzahrani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13610499.txt.
Description
Iman Alfagih and seven colleagues pack a lung cancer drug into targeted nanoparticles to attack hard breast cancers, in a paper dated twenty twenty-six. The drug, osimertinib, blocks a growth receptor that many triple-negative breast tumors carry in excess. Swallowed doses spread through the body and cause side effects. The team's particles are coated with chitosan, a shell sugar, to home in on tumor cells.
The particles stayed under two hundred nanometers and released the drug slowly over a day. In two breast cancer cell lines, the coated particles killed cells at far lower doses than uncoated ones. They entered the aggressive line well and pushed more cells into suicide. Migration of the cells also slowed.
Catalog record
| CREATOR | Iman M. Alfagih, Maryam Alfagih, Alanood Almurshedi, Basmah Aldosari, Bushra Alquadeib, Baraa Hajjar, Shahad Almogheerah, Rund Alzahrani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |